| Biomarkers in chronic kidney disease: a review RG Fassett, SK Venuthurupalli, GC Gobe, JS Coombes, MA Cooper, ... Kidney international 80 (8), 806-821, 2011 | 600 | 2011 |
| Astaxanthin: a potential therapeutic agent in cardiovascular disease RG Fassett, JS Coombes Marine drugs 9 (3), 447-465, 2011 | 454 | 2011 |
| Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician’s expectation be matched by the reality? CA Houghton, RG Fassett, JS Coombes Oxidative medicine and cellular longevity 2016 (1), 7857186, 2016 | 272 | 2016 |
| Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study KP Koh, RG Fassett, JE Sharman, JS Coombes, AD Williams American Journal of Kidney Diseases 55 (1), 88-99, 2010 | 259 | 2010 |
| Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis B Bose, SV Badve, SS Hiremath, N Boudville, FG Brown, A Cass, ... Nephrology Dialysis Transplantation 29 (2), 406-413, 2014 | 258 | 2014 |
| Detection of glomerular bleeding by phase-contrast microscopy RG Fassett, BA Horgan, TH Mathew The Lancet 319 (8287), 1432-1434, 1982 | 242 | 1982 |
| Astaxanthin in cardiovascular health and disease RG Fassett, JS Coombes Molecules 17 (2), 2030-2048, 2012 | 234 | 2012 |
| Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and … PL Drury, R Ting, D Zannino, C Ehnholm, J Flack, M Whiting, R Fassett, ... Diabetologia 54, 32-43, 2011 | 233 | 2011 |
| Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease A Crawford, RG Fassett, DP Geraghty, DA Kunde, MJ Ball, IK Robertson, ... Gene 501 (2), 89-103, 2012 | 228 | 2012 |
| Astaxanthin, oxidative stress, inflammation and cardiovascular disease RG Fassett, JS Coombes Future cardiology 5 (4), 333-342, 2009 | 213 | 2009 |
| Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease NA Smart, AD Williams, I Levinger, S Selig, E Howden, JS Coombes, ... Journal of Science and Medicine in Sport 16 (5), 406-411, 2013 | 196 | 2013 |
| Oxidative stress biomarkers as predictors of cardiovascular disease NA Strobel, RG Fassett, SA Marsh, JS Coombes International journal of cardiology 147 (2), 191-201, 2011 | 194 | 2011 |
| Sulforaphane: translational research from laboratory bench to clinic CA Houghton, RG Fassett, JS Coombes Nutrition reviews 71 (11), 709-726, 2013 | 188 | 2013 |
| Antioxidant therapy in hemodialysis patients: a systematic review JS Coombes, RG Fassett Kidney international 81 (3), 233-246, 2012 | 185 | 2012 |
| Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection AC Bulmer, JT Blanchfield, I Toth, RG Fassett, JS Coombes Atherosclerosis 199 (2), 390-396, 2008 | 181 | 2008 |
| Taming the chronic kidney disease epidemic: a global view of surveillance efforts J Radhakrishnan, G Remuzzi, R Saran, DE Williams, N Rios-Burrows, ... Kidney international 86 (2), 246-250, 2014 | 180 | 2014 |
| A novel hypoxia-inducible factor− prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial RA Brigandi, B Johnson, C Oei, M Westerman, G Olbina, J De Zoysa, ... American Journal of Kidney Diseases 67 (6), 861-871, 2016 | 176 | 2016 |
| Guidelines for glycerol use in hyperhydration and rehydration associated with exercise SP Van Rosendal, MA Osborne, RG Fassett, JS Coombes Sports Medicine 40, 113-139, 2010 | 157 | 2010 |
| Palliative care in end‐stage kidney disease RG Fassett, IK Robertson, R Mace, L Youl, S Challenor, R Bull Nephrology 16 (1), 4-12, 2011 | 140 | 2011 |
| A Multi-Center Comparison of O2peak Trainability Between Interval Training and Moderate Intensity Continuous Training CJ Williams, BJ Gurd, JT Bonafiglia, S Voisin, Z Li, N Harvey, I Croci, ... Frontiers in physiology 10, 19, 2019 | 136 | 2019 |
